Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-EBV TCR-T in Relapsed/Refractory EBV-positive Lymphoma
NCT07162012Phase 1Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in EBV-positive lymphoma, sponsored by Shanghai General Hospital. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Sep 2025; status: recruiting.
02
Conditions
EBV-positive lymphoma
Beyond the preview
Go deeper on NCT07162012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162012.